📰 Immunic News
Page 14 - Immunic News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Immunic. Real-time updates on events, politics, business and more.
February 2, 2022
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...
December 14, 2021
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...
December 14, 2021
DGAP-News: Immunic, Inc. / Key word(s): Study results Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a
December 9, 2021
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...
November 23, 2021
DGAP-News: Immunic, Inc. / Key word(s): Conference Immunic, Inc. to Participate in the Piper Sandler & Co. 33rd Annual Virtual Healthcare Conference 23.11.2021 / 12:30 The issuer
November 23, 2021
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...
November 23, 2021
DGAP-News: Immunic, Inc. / Key word(s): Conference Immunic, Inc. to Participate in the Piper Sandler & Co. 33rd Annual Virtual Healthcare Conference 23.11.2021 / 12:30 The issuer is solely responsible for the content of this announcement. Immunic, Inc. to Participate in the Piper Sandler &am...
November 23, 2021
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...
November 4, 2021
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...
November 1, 2021
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...